
Two Posters at ESMO Congress 2025 Highlight Immutep’s Focus on Changing Treatment Landscape in First Line Non-Small Cell ...
Novel combination of efti with KEYTRUDA® and chemotherapy generates strong response rates across all PD-L1 expression levels in first line non-small cell lung cancer (1L NSCLC) including 61.7% ORR in low & no PD-L1 (TPS <50%), well above 40.8% from …